Abstract

We have developed an easy and efficient protocol for the synthesis of a series of some novel substituted-(5-hydroxy-3-phenylisoxazol-4-yl)-1,3-dimethyl-1H-chromeno[2,3-d]pyrimidine-2,4(3H,5H)-dione/3,3-dimethyl-2H-xanthen-1(9H)-one derivatives (4a–j) via p-TSA catalyzed reaction of 1,3-dimethylbarbituric acid/dimedone, substituted salicylaldehyde/2-hydroxy-nepthaldehyde and 3-phenyl-5-isoxazolone was administered in refluxed temperature in the presence of aqueous ethanol. All the obtained compounds were evaluated for their therapeutic effect using pharmacological and computational investigations, and structures were confirmed using analytical and spectroscopic techniques. Absorption spectra were recorded in six different solvents such as polar protic, polar aprotic, and nonpolar solvents, λmax of all the compounds are appeared at bathochromic shift towards the longer wavelength due to the π-π* & n-π* transitions. The results of pharmacological investigations revealed that the compounds 4c, 4e, and 4h possess excellent cytotoxicity efficacy, and compounds 4c, 4d, 4h, and 4i have shown better anti-TB efficiency. The SAR study shows the importance of the electron-withdrawing group and additional phenyl nucleus enhancing the biological potency of the compounds. The results of the in silico molecular docking studies revealed that the compounds 4c and 4h effectively interacted with P38 MAP kinase (-10.9 kcal/mol) and InhA-Enoyl-Acyl Carrier Protein Reductase (-11.0 kcal/mol), respectively. Further, the molecular dynamics (MD) simulation studies revealed that the compounds 4c and 4h stabilized the macromolecular structures in terms of RMSD, RMSF, the Radius of gyration, and SASA compared to their unbound and standard compound bound structures. DFT study suggested that the compounds are chemically and biologically more reactive due to less energy gap.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.